Semiquantitative measurements of standardized uptake value in assessment of response and outcomes in patients with lymphoma
Abstract Objectives To evaluate the accuracy of semiquantitative measurements of standardized uptake value (ΔSUV max ) in the assessment of response to treatment in patients with lymphoma. Background Positron emission tomography (PET) with 2-[18 F]-fluoro-2-deoxy-D-glucose is an essential tool for a...
Saved in:
Published in | The Egyptian journal of haematology : the official journal of the Egyptian Society of Haematology Vol. 48; no. 2; pp. 175 - 184 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Medknow Publications and Media Pvt. Ltd
01.04.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Abstract Objectives To evaluate the accuracy of semiquantitative measurements of standardized uptake value (ΔSUV max ) in the assessment of response to treatment in patients with lymphoma. Background Positron emission tomography (PET) with 2-[18 F]-fluoro-2-deoxy-D-glucose is an essential tool for accurate staging and early and late therapy response assessments in all 2-[18 F]-fluoro-2-deoxy-D-glucose -avid histologies. Patients and methods The study included 73 patients diagnosed as having diffuse large B-cell lymphoma or Hodgkin’s disease. PET/CT examinations were performed at baseline (PET0), then after 2 cycles of chemotherapy (PET 2), and after 4 cycles of chemotherapy (PET4). PET scans were analyzed according to Deauville five-point scale, and cutoff values for changes in the maximum standardized uptake value (SUV max ). The change in activity (ΔSUV) from initial (SUV max1 ) to later scans (SUV max2 ) was calculated. Biopsy was also taken when PET4 was visually positive but delta SUV max was negative or in case of new lesions if other sites have improved. Results In comparison with the results of biopsy, ΔSUV0-2 had 80% sensitivity, 94.1% specificity, and 90.91% accuracy, with significant P value of 0.001. Moreover, ΔSUV0–4 had sensitivity of 80%, specificity of 100%, and accuracy of 95.45%, with high agreement k ( P ) 0.861 with significant P value less than 0.001. On the contrary, the visual five-point scale analysis specificity was 17.65% and accuracy was 36.36%, with insignificant P value less than 0.321. Neither the Deauville criteria nor ΔSUV max was significantly associated with time to progression and overall survival. Conclusion ΔSUV max is comparable to biopsy and significantly more accurate than Deauville criteria in response assessment to chemotherapy. |
---|---|
AbstractList | Abstract Objectives To evaluate the accuracy of semiquantitative measurements of standardized uptake value (ΔSUV max ) in the assessment of response to treatment in patients with lymphoma. Background Positron emission tomography (PET) with 2-[18 F]-fluoro-2-deoxy-D-glucose is an essential tool for accurate staging and early and late therapy response assessments in all 2-[18 F]-fluoro-2-deoxy-D-glucose -avid histologies. Patients and methods The study included 73 patients diagnosed as having diffuse large B-cell lymphoma or Hodgkin’s disease. PET/CT examinations were performed at baseline (PET0), then after 2 cycles of chemotherapy (PET 2), and after 4 cycles of chemotherapy (PET4). PET scans were analyzed according to Deauville five-point scale, and cutoff values for changes in the maximum standardized uptake value (SUV max ). The change in activity (ΔSUV) from initial (SUV max1 ) to later scans (SUV max2 ) was calculated. Biopsy was also taken when PET4 was visually positive but delta SUV max was negative or in case of new lesions if other sites have improved. Results In comparison with the results of biopsy, ΔSUV0-2 had 80% sensitivity, 94.1% specificity, and 90.91% accuracy, with significant P value of 0.001. Moreover, ΔSUV0–4 had sensitivity of 80%, specificity of 100%, and accuracy of 95.45%, with high agreement k ( P ) 0.861 with significant P value less than 0.001. On the contrary, the visual five-point scale analysis specificity was 17.65% and accuracy was 36.36%, with insignificant P value less than 0.321. Neither the Deauville criteria nor ΔSUV max was significantly associated with time to progression and overall survival. Conclusion ΔSUV max is comparable to biopsy and significantly more accurate than Deauville criteria in response assessment to chemotherapy. |
Audience | Academic |
Author | Hebesh, Eman Al-Agizy, Hagar El-Ghany, Ashraf Abd Ahmed, Mohamed Gohar, Suzy Tawfek, Eman |
Author_xml | – sequence: 1 fullname: Al-Agizy, Hagar – sequence: 2 fullname: Tawfek, Eman – sequence: 3 fullname: El-Ghany, Ashraf Abd – sequence: 4 fullname: Ahmed, Mohamed – sequence: 5 fullname: Hebesh, Eman – sequence: 6 fullname: Gohar, Suzy |
BookMark | eNptkUtLxTAQhbNQ8Ll0HxDc9ZqkvU27FPEFggvdl2kzsdG2qZ1UUf-8qYooyDAMDN85i3N22MbgB2TsQIpVJkV6jA_tKm6V6UqpDbYtpRSJFLneYvtED0IIqdallOtt9n6LvXuaYQguQHDPyHsEmifscQjEveUUYDAwGfeGhs9jgEfkz9DNyN3AgQiJFnZBJ6TRD4Q8KrifQ-N7pAUbo_Wn34sLLe9e-7H1PeyxTQsd4f733WV352d3p5fJ9c3F1enJddIoJUNSAxZpLeq8kNaIGvImhaw0pUWhtDKpluu1LQxYnUtQpVa6Bg2ZwUaoAm26yw6_bO-hw8oN1ocJmt5RU53ovMjyVJZFpFb_UHFMDKiJ-VoX_38ER78ELUIXWvLdHFyM4C-YfIHN5IkmtNU4uR6m10qKaumrWrr66Sv9AMG8kH8 |
Cites_doi | 10.1016/S1470-2045(16)30093-6 10.1053/j.semnuclmed.2017.09.007 10.3390/cancers12030601 10.2967/jnumed.107.042093 10.1056/NEJMoa1708566 10.1182/blood-2010-12-327767 10.1053/j.semnuclmed.2020.05.001 10.1007/s11899-016-0318-1 10.1200/JCO.2015.63.1119 10.1200/JCO.2017.76.8093 10.1007/s00259-013-2435-6 10.1200/JCO.2014.58.9846 10.1182/blood-2011-06-359943 10.1053/j.semnuclmed.2020.07.002 |
ContentType | Journal Article |
Copyright | COPYRIGHT 2023 Medknow Publications and Media Pvt. Ltd. |
Copyright_xml | – notice: COPYRIGHT 2023 Medknow Publications and Media Pvt. Ltd. |
DBID | AAYXX CITATION |
DOI | 10.4103/ejh.ejh_47_22 |
DatabaseName | CrossRef |
DatabaseTitle | CrossRef |
DatabaseTitleList | CrossRef |
DeliveryMethod | fulltext_linktorsrc |
EndPage | 184 |
ExternalDocumentID | A768463198 10_4103_ejh_ejh_47_22 |
GroupedDBID | AAYXX ABDBF ABXLX ACGFS AFWDF ALMA_UNASSIGNED_HOLDINGS CITATION H13 IAO IEA IHR IHW ITC KQ8 OVD RMW TEORI W3E |
ID | FETCH-LOGICAL-c221t-bae83b0b681fd0ba6c3a49d9fe0272d37155f8daf761a29727ba7a4dec028ef3 |
ISSN | 1110-1067 |
IngestDate | Fri Feb 23 00:21:53 EST 2024 Wed Jan 10 04:30:57 EST 2024 Tue Aug 20 22:00:10 EDT 2024 Thu Sep 12 20:35:24 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c221t-bae83b0b681fd0ba6c3a49d9fe0272d37155f8daf761a29727ba7a4dec028ef3 |
PageCount | 10 |
ParticipantIDs | gale_infotracmisc_A768463198 gale_infotracacademiconefile_A768463198 gale_healthsolutions_A768463198 crossref_primary_10_4103_ejh_ejh_47_22 |
PublicationCentury | 2000 |
PublicationDate | 2023-04-00 20230401 |
PublicationDateYYYYMMDD | 2023-04-01 |
PublicationDate_xml | – month: 04 year: 2023 text: 20230401 day: 01 |
PublicationDecade | 2020 |
PublicationTitle | The Egyptian journal of haematology : the official journal of the Egyptian Society of Haematology |
PublicationYear | 2023 |
Publisher | Medknow Publications and Media Pvt. Ltd |
Publisher_xml | – name: Medknow Publications and Media Pvt. Ltd |
References | Lin (CIT0008-20240902) 2007; 48 Press (CIT0004-20240902) 2016; 34 Schöder (CIT0006-20240902) 2020; 135 Naguib (CIT0011-20240902) 2021; 52 Mamot (CIT0018-20240902) 2015; 33 Pregno (CIT0014-20240902) 2012; 119 Ribeiro (CIT0013-20240902) 2021; 40 van Waarde (CIT0015-20240902) 2004; 45 Dührsen (CIT0017-20240902) 2018; 36 Cheson (CIT0001-20240902) 2018; 48 Schuster (CIT0019-20240902) 2017; 377 Sorace (CIT0010-20240902) 2020; 50 Itti (CIT0016-20240902) 2013; 40 Voltin (CIT0002-20240902) 2020; 2 Kreissl (CIT0007-20240902) 2016; 17 Casasnovas (CIT0009-20240902) 2011; 118 Gillman (CIT0005-20240902) 2020; 50 Barrington (CIT0003-20240902) 2016; 11 |
References_xml | – volume: 17 start-page: 1453 year: 2016 ident: CIT0007-20240902 article-title: Cancer-related fatigue in patients with and survivors of Hodgkin’s lymphoma: a longitudinal study of the German Hodgkin Study Group publication-title: Lancet Oncol doi: 10.1016/S1470-2045(16)30093-6 contributor: fullname: Kreissl – volume: 48 start-page: 76 year: 2018 ident: CIT0001-20240902 article-title: PET/CT in lymphoma: current overview and future directions publication-title: Semin Nucl Med doi: 10.1053/j.semnuclmed.2017.09.007 contributor: fullname: Cheson – volume: 2 start-page: 601 year: 2020 ident: CIT0002-20240902 article-title: FDG-PET imaging for Hodgkin and diffuse large B-cell lymphoma – an updated overview publication-title: Cancers doi: 10.3390/cancers12030601 contributor: fullname: Voltin – volume: 48 start-page: 1626 year: 2007 ident: CIT0008-20240902 article-title: Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis publication-title: J Nucl Med doi: 10.2967/jnumed.107.042093 contributor: fullname: Lin – volume: 52 start-page: 1 year: 2021 ident: CIT0011-20240902 article-title: Role of PET/CT in initial evaluation of lymphoma patients publication-title: Egypt J Rad Nucl Med contributor: fullname: Naguib – volume: 40 start-page: 281 year: 2021 ident: CIT0013-20240902 article-title: Semiquantitative analysis of interim 18F-FDG PET is superior in predicting outcome in Hodgkin lymphoma patients compared to visual analysis publication-title: Rev Esp Med Nucl Imagen Mol (Engl Ed) contributor: fullname: Ribeiro – volume: 377 start-page: 2545 year: 2017 ident: CIT0019-20240902 article-title: Chimeric antigen receptor T cells in refractory B-cell lymphomas publication-title: N Engl J Med doi: 10.1056/NEJMoa1708566 contributor: fullname: Schuster – volume: 118 start-page: 37 year: 2011 ident: CIT0009-20240902 article-title: SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma publication-title: Blood doi: 10.1182/blood-2010-12-327767 contributor: fullname: Casasnovas – volume: 50 start-page: 488 year: 2020 ident: CIT0010-20240902 article-title: Imaging for response assessment in cancer clinical trials publication-title: Semin Nucl Med doi: 10.1053/j.semnuclmed.2020.05.001 contributor: fullname: Sorace – volume: 11 start-page: 185 year: 2016 ident: CIT0003-20240902 article-title: PET scans for staging and restaging in diffuse large B-cell and follicular lymphomas publication-title: Curr Hematol Malign Rep doi: 10.1007/s11899-016-0318-1 contributor: fullname: Barrington – volume: 34 start-page: 2020 year: 2016 ident: CIT0004-20240902 article-title: US intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose–positron emission tomography imaging: Southwest Oncology Group S0816 publication-title: J Clin Oncol doi: 10.1200/JCO.2015.63.1119 contributor: fullname: Press – volume: 36 start-page: 2024 year: 2018 ident: CIT0017-20240902 article-title: Positron emission tomography-guided therapy of aggressive non-Hodgkin lymphomas (PETAL): a multicenter, randomized phase III trial publication-title: J Clin Oncol doi: 10.1200/JCO.2017.76.8093 contributor: fullname: Dührsen – volume: 40 start-page: 1312 year: 2013 ident: CIT0016-20240902 article-title: An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ΔSUVmax publication-title: Eur J Nucl Med Mol Imaging doi: 10.1007/s00259-013-2435-6 contributor: fullname: Itti – volume: 33 start-page: 2523 year: 2015 ident: CIT0018-20240902 article-title: Final results of a prospective evaluation of the predictive value of interim positron emission tomography in patients with diffuse large B-cell lymphoma treated with R-CHOP-14 (SAKK 38/07) publication-title: J Clin Oncol doi: 10.1200/JCO.2014.58.9846 contributor: fullname: Mamot – volume: 119 start-page: 2066 year: 2012 ident: CIT0014-20240902 article-title: Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP publication-title: Blood doi: 10.1182/blood-2011-06-359943 contributor: fullname: Pregno – volume: 135 start-page: 2224 year: 2020 ident: CIT0006-20240902 article-title: Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 publication-title: Clin Trial Blood contributor: fullname: Schöder – volume: 45 start-page: 695 year: 2004 ident: CIT0015-20240902 article-title: Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model publication-title: J Nucl Med contributor: fullname: van Waarde – volume: 50 start-page: 505 year: 2020 ident: CIT0005-20240902 article-title: Update on quantitative imaging for predicting and assessing response in oncology publication-title: Semin Nucl Med doi: 10.1053/j.semnuclmed.2020.07.002 contributor: fullname: Gillman |
SSID | ssj0001259115 |
Score | 2.2673013 |
Snippet | Abstract Objectives To evaluate the accuracy of semiquantitative measurements of standardized uptake value (ΔSUV max ) in the assessment of response to... |
SourceID | gale crossref |
SourceType | Aggregation Database |
StartPage | 175 |
SubjectTerms | Cancer Chemotherapy Development and progression Dextrose Glucose Measurement Medical research Medicine, Experimental Non-Hodgkin's lymphomas Patient outcomes PET imaging Sport-utility vehicles Vincristine |
Title | Semiquantitative measurements of standardized uptake value in assessment of response and outcomes in patients with lymphoma |
Volume | 48 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF6F9MIFgQBRKLAHBIfK4PfaRxdSKqRyIUi9WftynZDEJThChH_Mr2DGu34kyqFwiSx7d7XxfJoZz858Q8grN9YRE1HixIn0nZCrwkmZTB3JuNv0E2E-1jtffo4vvoafrqKr0ejPIGtpU4u3cnuwruR_pAr3QK5YJfsPku0WhRtwDfKFX5Aw_N5Kxl_0cvZ9w1dNoRimAC37iF-TotEGCmZb8Cs3NzX_pk-R3rthCuEdKScOXZtkWXOaUG1q2K82OeaGedWWwS1-gfgrq8znPdQm2M5sZqP61sMtORLCGpKnNn_kEGVFPZzfppHiAUM_v8PlwsmuZ1tTVsGv-bqPxU75z0Ib3Y7nEt39TKjTycL5WILaazThj3LNi74CIyuXJuB7WZUcLu0TGwnxg0ECjVHeHmaauKa9R6vdw2SAYn-gqj3TscVafc80qts3KKHnIrGFnoPln5d5yHJTRb1L3L1nULs0R_jAwgVynNpNv0OOfFCKoI2PsrMPZ-eDiGAElidqugHZP2JIYXGNdztb2HGixm0ap3WKpvfJPfs1QzMDzQdkpFcPye99WNIhLGlV0CEsqYElbWBJZyvawxKHtrCkMIO2sMRhLSwpwpK2sHxEpueT6fsLx_b4cKTve7UjuE4C4Yo48QrlCh7LgIepSgvt-qAmAgb-bpEoXrDY434K3rbgjIdKS3CMdRE8JuNVtdJPCGWCqVh5nlAqDqUKBVfIFAVGykuYDJJj8rp9Z_mNYXLJDwromLzEN5qbQuROT-QZnlnHYLJgqTfNCERKveaS21IW2Aiyqe2MPNkZCbpbDh4_ve2enpG7PeJPyLheb_Rz8IZr8cLC6C9k9cId |
link.rule.ids | 315,783,787,27936,27937 |
linkProvider | EBSCOhost |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Semiquantitative+measurements+of+standardized+uptake+value+in+assessment+of+response+and+outcomes+in+patients+with+lymphoma&rft.jtitle=The+Egyptian+journal+of+haematology+%3A+the+official+journal+of+the+Egyptian+Society+of+Haematology&rft.au=Al-Agizy%2C+Hagar+A&rft.au=Tawfek%2C+Eman+A&rft.au=Abd+El-Ghany%2C+Ashraf+E&rft.au=Ahmed%2C+Mohamed+E&rft.date=2023-04-01&rft.issn=1110-1067&rft.volume=48&rft.issue=2&rft.spage=175&rft.epage=184&rft_id=info:doi/10.4103%2Fejh.ejh_47_22&rft.externalDBID=n%2Fa&rft.externalDocID=10_4103_ejh_ejh_47_22 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1110-1067&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1110-1067&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1110-1067&client=summon |